Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 28;4(1):vdac157.
doi: 10.1093/noajnl/vdac157. eCollection 2022 Jan-Dec.

Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation

Vincent Fougner  1 , Benedikte Hasselbalch  1 , Ulrik Lassen  1 , Joachim Weischenfeldt  2 , Hans Skovgaard Poulsen  1 , Thomas Urup  1
Affiliations
Review

Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation

Vincent Fougner et al. Neurooncol Adv. .

Abstract

The introduction of targeted therapies to the field of oncology has prolonged the survival of several tumor types. Despite extensive research and numerous trials, similar outcomes have unfortunately not been realized for glioblastoma. For more than 15 years, the standard treatment of glioblastoma has been unchanged. This review walks through the elements that have challenged the success of previous trials and highlight some future promises. Concurrently, this review describes how institutions, through a multimodal and comprehensive strategy with 4 essential components, may increase the probability of finding a meaningful role for targeted therapies in the treatment of glioblastoma. These components are (1) prudent trial designs, (2) considered drug and target selection, (3) harnessed real-world clinical and molecular evidence, and (4) incorporation of translational research.

Keywords: glioblastoma; real-world evidence; targeted treatment; translational research; trial design.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Most common targets in concluded and ongoing glioblastoma trials (up to 1st of April 2020) Adapted from data collected by Cruz Da Silva et al. Index: VEGF: Vascular endothelial growth factor; RTK: Receptor tyrosine kinase; EGFR: Epidermal growth factor receptor; PDGFR: Platelet-derived growth factor receptor; VEGFR: Vascular endothelial growth factor receptor; mTOR: Mammalian target of rapamycin; HER2: Human epidermal receptor 2; HDAC: Histone deacetylase; PI3K-pathway: Phosphoinositide 3-kinases pathway.
See this image and copyright information in PMC

References

    1. Wen PY, Weller M, Lee EQ, et al. . Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22(8):1073–1113. - PMC - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, et al. . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. - PubMed
    1. Strobel H, Baisch T, Fitzel R, et al. . Temozolomide and other alkylating agents in glioblastoma therapY. Biomedicines. 2019;7(3):69. - PMC - PubMed
    1. Cruz Da Silva E, Mercier MC, Etienne-Selloum N, Dontenwill M, Choulier L. A systematic review of glioblastoma-targeted therapies in phases II, III, IV clinical trials. Cancers. 2021;13(8):1795. - PMC - PubMed
    1. Stupp R, Hegi ME, Mason WP, et al. . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466. - PubMed

LinkOut - more resources